Elsevier

Clinical Colorectal Cancer

Volume 6, Issue 3, September 2006, Pages 224-225
Clinical Colorectal Cancer

Case Report
Ocular Toxicity Related to Cetuximab Monotherapy in Patients with Colorectal Cancer

https://doi.org/10.3816/CCC.2006.n.040Get rights and content

Abstract

Cetuximab is a monoclonal antibody that specifically blocks the epidermal growth factor receptor pathway. Cetuximab is now a standard drug to treat refractory advanced colorectal cancer. The most common side effect is a rash, seen in most patients. Ocular toxicity is uncommon. We report 2 cases of ocular toxicity characterized by blepharitis and conjunctivitis related to cetuximab administration. Strategies for management are discussed.

References (8)

There are more references available in the full text version of this article.

Cited by (20)

  • Ocular side effects of oncological therapies: Review

    2024, Archivos de la Sociedad Espanola de Oftalmologia
  • Emergence of ocular toxicities associated with novel anticancer therapeutics: What the oncologist needs to know

    2022, Cancer Treatment Reviews
    Citation Excerpt :

    OAE frequency and severity: Cetuximab has been associated with dry eye (67%), blepharitis (63%), conjunctivitis (10–18%), and eyelid rash or hyperemia (38%) [6,60]. Other cetuximab associated OAEs in case reports include eye discomfort, foreign body sensation, tearing, and redness [61]. Overall class OAEs are mild and more common AEs include conjunctivitis (5%), growth of eyelashes (6%), blepharitis with increased lacrimation and eyelid irritation reported in 15% of patients [2,62].

  • Ocular toxicities of MEK inhibitors and other targeted therapies

    2016, Annals of Oncology
    Citation Excerpt :

    Cetuximab is an EGFR monoclonal antibody used to treat head and neck and advanced colorectal cancer. Multiple different ocular toxicities have been reported with the use of cetuximab, including corneal erosions [6], poliosis [7], eyelash trichomegaly [7–11], punctate keratitis [12], conjunctivitis, eyelid dermatitis and blepharitis [10, 13]. Panitumumab is an EGFR monoclonal antibody used in patients with advanced colorectal cancers.

  • Best practices in the management of toxicities related to anti-EGFR agents for metastatic colorectal cancer

    2010, European Journal of Oncology Nursing
    Citation Excerpt :

    Entropion or ectropion: inversion or eversion of the eyelid margin (Burtness et al., 2009) Ocular adverse events in response to anti-EGFR therapy affect approximately 15% of patients treated with cetuximab or panitumumab although severe toxicities are observed in <1% of patients treated with the antibodies as monotherapy (Basti, 2007; Dranko et al., 2006; Erbitux SmPC; Jean and Shah, 2008; Vectibix SmPC). According the Erbitux prescribing information, conjunctivitis was commonly observed with cetuximab, whereas blepharitis and keratitis were uncommon (Erbitux SmPC).

  • Uncommon Blepharitis

    2024, Journal of Clinical Medicine
View all citing articles on Scopus

Electronic forwarding or copying is a violation of US and International Copyright Laws.

Authorization to photocopy items for internal or personal use, or the internal or personal use of specific clients, is granted by CIG Media Group, LP, ISSN #1533-0028, provided the appropriate fee is paid directly to Copyright Clearance Center, 222 Rosewood Drive, Danvers, MA 01923 USA 978-750-8400.

View full text